- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.Fierce Biotech · 3d ago↗ source
- FDA panel endorses broader use of certain peptides<figure><div><img src="https://imgproxy.divecdn.com/d2JyuXgmLsPVrlZlLVlPLECICsiII5W1r34tQBQf49c/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjI3NzEwNTIwX0w2O…BioPharma Dive · 3d ago↗ source
- STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptidesThe panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.STAT